This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. MIRA, CMMB, QNTM, LPCN, UBX, BCTX, COCP, CING, BFRG, and EDSAShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include MIRA Pharmaceuticals (MIRA), Chemomab Therapeutics (CMMB), Quantum Biopharma (QNTM), Lipocine (LPCN), Unity Biotechnology (UBX), BriaCell Therapeutics (BCTX), Cocrystal Pharma (COCP), Cingulate (CING), Bullfrog AI (BFRG), and Edesa Biotech (EDSA). These companies are all part of the "medical" sector. Novus Therapeutics vs. MIRA Pharmaceuticals Chemomab Therapeutics Quantum Biopharma Lipocine Unity Biotechnology BriaCell Therapeutics Cocrystal Pharma Cingulate Bullfrog AI Edesa Biotech MIRA Pharmaceuticals (NASDAQ:MIRA) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Is MIRA or NVUS more profitable? Novus Therapeutics' return on equity of -133.49% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Novus Therapeutics N/A -133.49%-30.52% Does the media prefer MIRA or NVUS? In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than Novus Therapeutics. MarketBeat recorded 3 mentions for MIRA Pharmaceuticals and 0 mentions for Novus Therapeutics. MIRA Pharmaceuticals' average media sentiment score of 0.96 beat Novus Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment MIRA Pharmaceuticals Positive Novus Therapeutics Neutral Do analysts recommend MIRA or NVUS? MIRA Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,128.07%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe MIRA Pharmaceuticals is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer MIRA or NVUS? Novus Therapeutics received 249 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 66.84% of users gave Novus Therapeutics an outperform vote. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesNovus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% Which has more risk & volatility, MIRA or NVUS? MIRA Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Do institutionals and insiders hold more shares of MIRA or NVUS? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, MIRA or NVUS? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.52-2.19Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.15 SummaryMIRA Pharmaceuticals beats Novus Therapeutics on 11 of the 16 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.54M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.147.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.246.486.734.25Net Income-$16.01M$143.41M$3.22B$248.18M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.16-3.4%N/A+36.8%$4.54MN/A-0.147MIRAMIRA Pharmaceuticals2.8445 of 5 stars$1.12+8.7%$14.00+1,150.0%+36.5%$18.83MN/A-2.002Short Interest ↓CMMBChemomab Therapeutics3.5795 of 5 stars$1.30-3.4%$9.00+595.0%+92.9%$18.60MN/A-1.3020Upcoming EarningsShort Interest ↓News CoverageQNTMQuantum BiopharmaN/A$6.82-1.7%N/AN/A$18.45MN/A-0.44N/AUpcoming EarningsLPCNLipocine2.495 of 5 stars$3.42+4.1%$10.00+192.8%-28.4%$18.27M$11.20M-4.4910Upcoming EarningsAnalyst ForecastNews CoverageUBXUnity Biotechnology4.1199 of 5 stars$1.01+3.0%$5.33+428.1%-26.6%$17.38M$240,000.00-0.7760Analyst RevisionNews CoverageBCTXBriaCell Therapeutics1.7304 of 5 stars$4.67-6.6%$32.00+585.2%-86.3%$17.27MN/A-0.358COCPCocrystal Pharma2.4926 of 5 stars$1.66+0.3%$7.00+323.0%-4.4%$16.83MN/A-0.8910CINGCingulate2.5142 of 5 stars$4.26-2.1%$30.67+619.9%+350.8%$16.79MN/A-0.2920Short Interest ↑News CoverageBFRGBullfrog AI0.4747 of 5 stars$1.78+0.6%N/A-43.6%$16.75M$60,000.00-2.094Short Interest ↑EDSAEdesa Biotech3.103 of 5 stars$2.38-1.0%$21.00+784.2%-47.6%$16.68MN/A-1.2720Short Interest ↓ Related Companies and Tools Related Companies MIRA Alternatives CMMB Alternatives QNTM Alternatives LPCN Alternatives UBX Alternatives BCTX Alternatives COCP Alternatives CING Alternatives BFRG Alternatives EDSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
